Breaking AI & Tech News Analyzed

FDA Clearance Marks a Milestone for BioticsAI's Ultrasound AI CopilotRobhy Bustami, co‑founder and CEO of BioticsAI, announced that the company obtained FDA approval in January 2026, unlocking the ability to launch its fetal‑abnormality detection system in clinical settings.From Scrappy Prototype to Regulatory SuccessThe team built a functional prototype for under $100,000, an unusually low cost for a medical‑device startup. That early version helped them win TechCrunch Startup Battlefield 2023, providing visibility and credibility that accelerated investor interest.Prototype cost: $100kTechCrunch Battlefield win: 2023FDA approval received: January 2026Financial and Timeline Metrics Behind the ClearanceWhile the article does not disclose full fundraising numbers, the rapid prototype and battlefield win suggest a capital‑efficient path. Early regulatory engagement—pre‑submission meetings with the FDA— reduced uncertainty and compressed the typical multi‑year approval timeline.Early regulator meetings: pre‑submission phaseTypical FDA device timeline: 18‑36 months (compressed by early alignment)Why FDA Approval Shifts the AI‑Healthcare LandscapeGaining clearance validates the technical approach and signals to hospitals that the product meets rigorous safety standards. It also demonstrates a repeatable model for other AI‑driven diagnostics, encouraging more founders to embed regulatory strategy from day one.Creates a trusted entry point for hospital adoptionSets a precedent for AI‑based fetal imaging toolsHighlights the need for cross‑functional teams (engineers, clinicians, regulators)Looking Ahead: Expansion Beyond ObstetricsWith the FDA hurdle cleared, BioticsAI plans to deploy its technology across obstetric units and later broaden into other reproductive‑health applications. The founder emphasizes continued data collection, partnership growth, and potential international regulatory filings as the next growth levers.Phase 1: Hospital rollout in obstetrics (2026‑2027)Phase 2: Expansion into broader reproductive health diagnostics (2028+)Long‑term goal: Global market penetration with localized regulatory approvals

The Politicization of Science Donald Trump’s war on science has been vicious and hugely damaging, but it is worth noting that he has lost some of its biggest battles. Last year, Mr Trump demanded that US federal scientific and medical research funding be cut by about half. But the budget Congress passed in February actually delivered a slight increase in overall funding – although specific Trump targets such as the Centers for Disease Control and Prevention were cut. Resistance from Congress He also continues to chip away at science in other ways such as dismissing the board overseeing the National Science Foundation this week. Maga’s attacks on science have been nakedly political. Its defeats have been politics of a different sort, showing that the bipartisan pro-science consensus is still intact, and for the moment has the power to hold Mr Trump in check. A Global Trend What is happening in the US is not unique. Wherever rightwing populists triumph, science is likely to suffer. Jair Bolsonaro’s rule in Brazil saw him attack scientists and cut environmental funding. In India, Narendra Modi’s Hindu nationalist government purged the theory of evolution from school textbooks. In Britain, Reform UK has already attempted local government cuts, targeting net zero spending. The Changing Role of Scientists Scientists have tended to avoid party politics for a specific reason. Historians identify an implicit scientific social contract that emerged in western states after the second world war, which established the state as the main funder of research, but in theory discouraged direct political interference by government. Many scientists believe that engaging in politics endangers this compact: if scientists don’t bother politics, it won’t bother them. A New Era for Science and Politics Scientists are no longer just defending funding. They are defending the idea that science should be independent of politics. What scientists gain by organising protests, speaking to the public through their academies and now running for office is a better understanding of the changing public sphere that they are part of. The public may gain an ally against rightwing populism – and a deeper, more serious engagement with the scientific challenges facing society. Mr Trump set out to tame scientists. He may have politicised them instead.

The Journey from Prototype to ClearanceBuilding a medical device is fundamentally different from standard software development. This week on Build Mode, host Isabelle Johannessen sat down with Robhy Bustami, co-founder and CEO of BioticsAI, to discuss the arduous path from a $100,000 prototype to FDA clearance. Bustami, a Startup Battlefield winner, detailed how his team is building an AI copilot for ultrasound designed to detect fetal abnormalities. The conversation revealed that the traditional startup mantra of 'move fast and break things' is obsolete in the medical sector, replaced by a necessity for extreme precision and coordination.Market Validation and Resource AllocationThe episode provides a strategic look at the 'data' driving medtech success. BioticsAI's recognition as a Startup Battlefield winner serves as a key validation of their technology's potential. However, Bustami emphasized that the primary data point for founders is not just market traction, but the successful navigation of complex regulatory pathways. This requires a significant reallocation of resources—shifting focus from rapid feature deployment to ensuring safety, reliability, and compliance with FDA standards.Shifting the MedTech CultureThe core impact of this discussion lies in the cultural shift it highlights for the industry. As timelines for FDA approval remain uncertain, the ability to maintain team morale and investor confidence becomes a critical operational metric. Bustami noted that building in a regulated industry requires a foundation of trust rather than speed. This signals a broader trend where medtech startups must balance the pressure of hyper-growth with the ethical and legal responsibilities of patient safety.The Future of AI in Healthcare RegulationLooking ahead, the medtech landscape will likely see a consolidation of companies that prioritize long-term compliance over short-term hype. As more AI copilots enter the market, the winners will be those founders who master the art of 'slow and steady' innovation. The next wave of medical breakthroughs will depend not just on algorithmic superiority, but on the ability to build sustainable organizations capable of weathering the regulatory storm.

The Challenges of FDA Approval Surviving the long road to FDA approval isn’t just about building great technology — it’s about keeping your team motivated, finding the right investors, and learning how to operate when timelines are uncertain. Lessons from BioticsAI This week on Build Mode, Isabelle Johannessen sits down with Robhy Bustami, co-founder and CEO of BioticsAI, a Startup Battlefield-winning company building an AI copilot for ultrasound to help detect fetal abnormalities. From a $100,000 prototype to FDA clearance, Bustami shares what it actually takes to build in one of the most regulated industries in the world. Building a Medtech Startup In this episode, they break down what it really looks like to build a medtech startup, including where you can’t “move fast and break things” and that every milestone takes time, coordination, and trust. Key Takeaways Team motivation is crucial during the long FDA approval process Finding the right investors is essential for medtech startups Adaptability is key when dealing with uncertain timelines Future Outlook As the medtech industry continues to evolve, startups like BioticsAI will play a critical role in shaping the future of healthcare technology. With the right approach and mindset, these companies can overcome the challenges of FDA approval and make a lasting impact.

The 'Hacked' Tweet That Exposed the Whitecaps' Crisis Major League Soccer (MLS) Commissioner Don Garber found himself at the center of a diplomatic firestorm on Wednesday evening after his official X account posted a derogatory comment directed at British Columbia Premier David Eby. The post, which called the Premier a 'liar,' was deleted within hours, replaced by a statement claiming the account had been 'compromised.' A Public Insult and a Swift Denial The incident highlights the extreme pressure surrounding the Vancouver Whitecaps' ownership situation. The timeline of events reveals a rapid escalation: 8:00 PM PT: Garber's account posted 'Liar liar pants on fire' in response to a video from Premier Eby. 9:00 PM PT: The post was deleted. 10:00 PM PT: Garber posted an explanation stating his account was compromised and thanking Eby for a meeting. Garber was reportedly at dinner with US Soccer officials when the post went live, and his communications team has since confirmed the account was hacked. This is a rare public breach of protocol for Garber, who rarely manages his own social media. The Financial Reality Behind the Rhetoric Beneath the personal insult lies a complex business dispute regarding the Whitecaps' stadium lease. The club's ownership claims the current agreement with PavCo (the province's crown corporation) remains financially untenable despite recent renegotiations. Whitecaps CEO Axel Schuster has stated that the new lease is not a 'gamechanger' for the club. The core issue remains the lack of a viable path to profitability while playing at BC Place, leading the club to seek a new soccer-specific stadium. The Political Fallout and FIFA Context The spat occurred during a critical window for the Whitecaps, coinciding with FIFA's congress in Vancouver. Premier Eby responded to the attack by posting a video to his own X account, assuring fans that the province is 'at the table fighting hard to save the Whitecaps.' Despite these assurances, the club's ownership has revealed they have received no offers from local groups, leaving the future of the team hanging in the balance between a potential move to Las Vegas or Phoenix and a years-long wait for a new stadium. The Future Outlook: Relocation or Renovation? The 'hacked' tweet suggests that the relationship between MLS and the BC government has reached a breaking point. While the immediate crisis was managed with a denial, the underlying structural issues remain. Analysts predict that unless a new stadium deal is struck within the next 12-18 months, the Whitecaps are likely to become the first MLS team to relocate, with Las Vegas emerging as the most probable destination due to the lack of immediate political will in Vancouver.

The Trial Continues Elon Musk's court case against Sam Altman continues on Thursday, after a day of contentious exchanges during OpenAI's cross-examination of the Tesla CEO. Musk will face another round of questioning before his lawyer calls more witnesses, including OpenAI's president, Greg Brockman. The Dispute Over OpenAI's Founding Witness testimony and evidence has revealed formerly private emails, text messages and diary entries surrounding the formation of OpenAI, giving a behind-the-scenes look at how the tech behemoth was created. Many of the tech industry's most powerful players are named as witnesses and will give their account on the origins of Musk and Altman's bitter feud. Altman is set to testify later in the trial, which will last three weeks. Musk's Allegations Against OpenAI Musk, who co-founded OpenAI in 2015, is arguing that Altman, Brockman and OpenAI broke a foundational agreement when they shifted the company from a non-profit intent on bettering humanity into a for-profit structure. Musk claims that Altman and Brockman unjustly enriched themselves and should be removed from the company. He is also seeking the undoing of the for-profit conversion and $134bn in damages to be redirected to OpenAI's non-profit arm. OpenAI's Response OpenAI rejects Musk's allegations and is attempting to show that he was always aware of plans for creating a for-profit entity. The AI firm's attorneys have stated Musk is "motivated by jealousy" of OpenAI's success after he left the company in 2018 after a failed attempt to take control. OpenAI has emphasized that it is still overseen by a non-profit. The Implications of the Trial The trial, which began on Monday with jury selection at a federal courthouse in Oakland, California, has already produced dramatic moments and bold accusations. Musk and OpenAI's lead attorney William Savitt spent most of Wednesday in a heated back and forth, with the world's richest person becoming noticeably frustrated and saying that Savitt's questions "are designed to trick me". The Future of OpenAI Silicon Valley is intently watching the trial for both its blockbuster testimony and the potential effects it will have on the AI industry. OpenAI is intending to go public later this year at around a $1tn valuation, but if Musk succeeds in this case, it could greatly complicate that effort – an outcome that would also benefit Musk's own xAI artificial intelligence firm.

Salesforce's AI Roadmap Strategy Artificial intelligence continues to advance at a dizzying clip, forcing enterprises to develop and release new products quicker than ever or risk becoming irrelevant to a faster-moving competitor. Salesforce believes it has found a strategy that allows it to keep up even if it isn’t clear where AI is headed next. The customer management software giant is crowdsourcing its AI roadmap in real time. Crowdsourcing AI Development Salesforce is certainly not the only company to work intimately with its customers for feedback on its products. However, it’s notable considering the sheer size of the company, the pace of new product launches or fixes to existing ones, and the granular level of these relationships. These aren’t annual or even quarterly discussions. Salesforce is meeting with some customers as often as once a week. The Benefits of Customer Feedback “The 18,000 customers are a wellspring of information and a wealth of information that is really needed to get to customer success,” Jayesh Govindarajan, executive vice president at Salesforce AI, told TechCrunch in a recent interview. “The stack that we’ve built has resonated with these customers. Over time we can get context to be better, and as it gets better, and LLMs get better, agent systems do more and more fully autonomous behaviors. That’s a long-running innovation track and we’re going to invest in that.” Rapid Product Releases Salesforce credits its customers for the rate of its product releases. The company told TechCrunch that by letting its customers lead the way, it is able to build an AI product roadmap that can quickly react to where AI technology is headed. Customer Success Stories Engine, a travel management platform, meets with Salesforce weekly and gets access to AI tools before they’re released. PenFed, a federal credit union, developed an IT service management (ITSM) workflow on its own using existing tools and agents in Agentforce that worked well for the company. The Future of AI Development This strategy also allows the company to roll out solutions and workflows built by users to its broader customer base too. However, the downside to this approach is that it relies on the classic service sentiment that the customer is always right. Salesforce is hoping they are despite many enterprises still figuring out what role AI will play in their business, and many having yet to find value from the tech.

The Psychedelic Therapy Trials The US Department of Defense (DoD) is funding two studies into psychedelic therapy for active-duty soldiers with PTSD. The studies, which will involve 186 service personnel, will investigate the use of MDMA-assisted therapy to help soldiers process trauma and reduce symptoms of PTSD. The Research Details The studies will be conducted at the Walter Reed national military medical center and Emory University, with the goal of determining the safety and efficacy of MDMA-assisted therapy for soldiers with PTSD. The therapy involves multiple sessions of MDMA-assisted therapy, with the aim of helping soldiers process trauma and reduce symptoms of PTSD. The Data Analysis The studies will involve a total of 186 service personnel, with 91 military, guard, and reserve personnel set to receive three separate MDMA doses across 10 months at Walter Reed. The studies are expected to cost $4.9m each, with the funding signed off by former president Joe Biden as part of the National Defence Authorization Act in December 2023. The Impact Analysis The use of psychedelic therapy for soldiers with PTSD has the potential to revolutionize the way that the military approaches mental health. According to Rick Doblin, the founding president of the Multidisciplinary Association for Psychedelic Studies (Maps), "Helping people process trauma, whoever they are, is probably better than not." The therapy could also help to reduce the stigma surrounding mental health issues in the military. The Prediction If the studies are successful, MDMA-assisted therapy could become a standard treatment for soldiers with PTSD. The therapy could also have implications for the treatment of PTSD in civilians, and could potentially be used to address other mental health issues. However, there are also concerns about the potential risks of using psychedelic therapy, particularly in an active-duty setting.

The Leap from Ballet to New Careers Former ballet dancers share their journeys of transitioning to new careers, highlighting the challenges and opportunities they encountered. Finding New Purpose: Lana Jones' Journey to Midwifery Lana Jones, a former principal dancer at the Australian Ballet, discovered a new passion in midwifery. After the birth of her son, she felt a strong desire to pursue a career that wasn't about her, but about helping others. She enrolled in a midwifery course at medical school and now finds fulfillment in her work, particularly in making women feel safe during labor. From Ballet to the House of Lords: Baroness Deborah Bull's Story Baroness Deborah Bull, a former principal dancer at the Royal Ballet, was selected as a life peer in the House of Lords in 2018. She reflects on the similarities between performing on stage and working in the chamber, where she must prepare, research, and perform under pressure. Despite missing the physicality of ballet, she values her new role and the opportunity to contribute to important discussions. Embracing Change: Sarah Dolník's Path to Social Work Sarah Dolník, formerly a dancer with the Czech National Ballet, considered retirement during the 2020 Covid lockdown. She began studying social work and eventually left ballet at 27 to pursue a new career. Now a kindergarten teacher, she appreciates being part of decision-making conversations and values her newfound sense of purpose. Staying in the Performing Arts: Federico Bonelli's Experience Federico Bonelli, artistic director of Northern Ballet and former principal dancer at the Royal Ballet, shares his journey of staying within the performing arts while transitioning to a new role. His story highlights the importance of finding new passions and opportunities within one's existing field.